Simple Summary The identification of BRAF mutations in 1.5–3.5% of NSCLC patients
represents a step forward towards new targeted agents for tackling NSCLC. The positive …

According to clinical trials, BRAF kinase inhibitors in combination with MEK kinase inhibitors
are among the most promising chemotherapy regimens for the treatment of advanced BRAF …

BRAF protein kinase is a crucial player in melanoma, as it belongs to the highly oncogenic
RAS/RAF/MEK/ERK signaling pathway (Matallanas et al., 2011), is mutated in about 50% of …

Patients with melanoma with activating BRAF mutations (BRAF V600E/K) initially respond to
combination therapy of BRAF and MEK inhibitors. However, their clinical efficacy is limited …

Activating mutations in the BRAF gene are among the most prevalent kinase mutations in
human cancer. BRAF mutations are most frequent in patients with melanoma where they …

Recent progress in our understanding of the genetic alterations that occur in the
pathogenesis of melanoma provides exciting opportunities for therapy. The most important …

Activating mutations of the BRAF oncogene are present in approximately 5-10% of all
human malignancies and lead to constitutive activation of the mitogen activated protein …

The protein kinase B-Raf is a critical component of the Ras/MAPK signaling pathway. An
oncogenic B-Raf mutation that constitutively activates the kinase was identified in z50% of …

We describe a mechanism of tumorigenesis mediated by kinase-dead BRAF in the presence
of oncogenic RAS. We show that drugs that selectively inhibit BRAF drive RAS-dependent …

The mitogen-activated protein kinase (MAPK)/extracellular signal-regulated kinase (ERK)
pathway is frequently mutated in human cancer. This pathway consists of a small GTP …